

ASX Announcement

9 October 2023

Launch of Share Sale Facility for Unmarketable Parcels

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY] (**Antisense** or the **Company**), a biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce that it has established an unmarketable parcel share sale facility (**Facility**) for shareholders who hold fully paid ordinary shares in the Company (**Shares**) valued at less than \$500 (**Unmarketable Parcels**).

Based on the price of Shares at the close of trading on 6 October 2023 (**Record Date**) of \$0.07, a holding of less than 7,143 Shares constitutes an Unmarketable Parcel.

The Facility enables holders of Unmarketable Parcels to sell their Shares without having to act through a broker or incur any brokerage or handling costs. It will provide an opportunity for investors with small holdings, who may find it difficult or uneconomic to dispose of those Shares through normal means, to liquidate their position in a cost-effective manner. Antisense will bear all costs associated with the sale and transfer of Shares through the Facility (excluding tax consequences of the sale, which will be the responsibility of the relevant shareholders).

The Company values all of its shareholders, however, it incurs significant administrative costs maintaining such a large number of Unmarketable Parcels. By establishing this Facility, the Company expects the sale of the Unmarketable Parcels, through the Facility, will help to reduce the administrative costs, including printing and mailing costs and share registry expenses, that are associated with maintaining a large number of Unmarketable Parcels.

In accordance with the Company's constitution and the ASX Listing Rules, the attached letter (**Notice of Divestiture**) and share retention form (**Retention Form**) will be sent to all shareholders who hold an Unmarketable Parcel on the Record Date.

Shareholders with Unmarketable Parcels wishing to take advantage of the Facility and have their Shares sold by the Company do not need to take any action. Shareholders who hold an Unmarketable Parcel and wish to retain their Shares will need complete and return to the Company's share registry, Boardroom Pty Limited, the Retention Form confirming that they wish to keep its Unmarketable Parcel, by no later than 5pm, AEDT, on Friday 24 November 2023 (**Closing Date**). Any shareholder who does not return the Retention Form and holds an Unmarketable Parcel by the Closing Date will have their Shares sold through the Facility.

The Company may arrange for the sale of the Shares under the Facility by way of an on-market sale, or in any way they consider reasonable in the circumstances (e.g. off-market sale or private treaty). The proceeds from the sale will be dealt with in accordance with the Company's constitution and will be remitted to participating Shareholders as soon as practicable following settlement of all Shares sold through the Facility.

The sale price will be determined once all of the Shares under the program are sold. Each shareholder will receive their proportionate share of the sale proceeds for all Shares sold through the Facility. If all or some of the Shares are sold off-market, the sale price for those Shares will be the price that the ANP directors have been able to negotiate with the acquirer/s.

Key Dates

Event	Date
Record Date	6 October 2023
Announcement to ASX	9 October 2023
Letters sent to eligible shareholders	11 October 2023
Retention Forms due date	24 November 2023

The timetable is indicative only and is subject to change. The Company reserves the right to amend the dates at its discretion and without notice, subject to the ASX Listing Rules and the Corporations Act 2001 (Cth).

Pursuant to clause 8A of the Company's constitution and Rule 15.13 of the ASX Listing Rules, the Company has the ability to facilitate the sale of Unmarketable Parcels.

The Company does not provide any recommendations or advice as to whether Shareholders holding an Unmarketable Parcel should sell or retain their Shares.

Attached to this announcement is a copy of the Notice of Divestiture and the Retention Form that will be sent to shareholders who hold an Unmarketable Parcel on the Record Date.

~ ENDS ~

This announcement has been authorised for release by the Board.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial in non-ambulant subjects with DMD.

For more information, please contact info@antisense.com.au

[Shareholder Name]
[Shareholder Address 1]
[Shareholder Address 2]
[Shareholder Address 3]
[Shareholder Address 4]

This letter contains important information regarding your shareholding in Antisense Therapeutics Limited (ASX: ANP) and requires your immediate attention.

9 October 2023

Dear Shareholder,

Unmarketable Parcels Share Sale Facility – Notice of Divestiture

Antisense Therapeutics (ASX:ANP) (**Antisense** or the **Company**) is pleased to advise that it has established an unmarketable parcel share sale facility (**Facility**) for shareholders who hold fully paid ordinary shares in the Company (**Shares**) valued at less than \$500 (**Unmarketable Parcel**) at the close of trading on 6 October 2023 (**Record Date**).

Based on the price of Shares at the Record Date of \$0.07, a holding of less than 7,143 Shares constitutes an Unmarketable Parcel.

The Company appreciates that Unmarketable Parcels can be difficult or expensive to sell, so the Facility is being offered to enable shareholders who hold an Unmarketable Parcel to sell their Shares without having to act through a broker or pay brokerage or handling fees. The Company will pay all costs associated with the sale and transfer of Shares through the Facility (excluding any tax consequences of the sale, which will be the responsibility of relevant shareholders). This Facility will allow holders of Unmarketable Parcels to monetise their otherwise unmarketable holdings.

The sale of Unmarketable Parcels through the Facility will also benefit the Company, as it is expected to significantly reduce the administrative costs associated with maintaining a large number of small shareholdings on the Company's share register.

Pursuant to clause 8A of the Company's constitution and Rule 15.13 of the ASX Listing Rules, the Company has the ability to facilitate the sale of Unmarketable Parcels.

Why are you receiving this letter?

Our record indicates that you held an Unmarketable Parcel of Shares based on the price of Shares of \$0.07 as at close of trade on the Record Date. Unless you advise the Company by 5pm (AEDT) on Friday 24 November 2023 (**Closing Date**) that you do **NOT** wish to sell your Shares, the Company intends to sell your Shares through the Facility in accordance with clause 8A of the Company's constitution and rule 15.13 of the ASX Listing Rules.

To advise the Company that you do **NOT** wish to sell your Shares, you must complete the share retention form (**Retention Form**) enclosed with this letter, and return it to the Company's share registry, Boardroom Pty Limited (**Share Registry**), in accordance with the instructions on the Retention Form, prior to the Closing Date.

If, at the Closing Date, the value of your Shares has increased such that you no longer have an Unmarketable Parcel (e.g., due to an increase in the market price of Shares or the number of Shares you hold), your Shares will **NOT** be sold.

If you have multiple holdings of Shares which, if aggregated, would not constitute an Unmarketable Parcel, you may contact the Share Registry at 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) to amalgamate your holdings. In these circumstances, your Shares will not be sold.

Please also note that pursuant to clause 8A of the Constitution and rule 15.13.5 of the ASX Listing Rules, the Company will not sell your Shares in the event that a third party announces a takeover offer for the Company.

In accordance with its continuous disclosure obligations, the Company may release information to the ASX which may affect your decision as to whether you wish to sell or retain your Shares. If such information is released, it will be published on the ASX website www.asx.com.au (ASX code: ANP) and on the Company's website (www.antisense.com.au).

You should be aware that the fact that's your holding of shares is described in this letter as an "unmarketable parcel" does not mean that you cannot sell your Shares at any time. The use of the term "unmarketable parcel" in this letter is to identify the value of Shares which are eligible for sale through the Facility.

What do you need to do?

As a holder of an Unmarketable Parcel as at the Record Date, your options are set out below.

OPTION 1 – Sell your Unmarketable Parcel

If you **WISH TO SELL** your Shares through the Facility, you should **TAKE NO ACTION**. By refraining from taking any action, you will be deemed to have irrevocably appointed the Company as your agent to:

- (a) sell, or procure the sale of, all of your Shares at a price to be determined, without any costs being incurred by you; *and*
- (b) deal with the proceeds of the sale as set out in this letter.

The proceeds from the sale of your Shares will be dealt with in accordance with the Company's constitution and will be remitted to participating shareholders as soon as practicable following settlement of all Shares sold through the Facility.

OPTION 2 – Retain your Unmarketable Parcel

If you **DO NOT WISH TO SELL** your Unmarketable Parcel, you **MUST OPT-OUT** of the Facility by completing and returning the enclosed Retention Form in accordance with the instructions on the Retention Form so that it is received by the Share Registry prior to the Closing Date.

Key Dates

The key dates in relation to the Facility are set out below:

Event	Date
Record Date	6 October 2023
Announcement to ASX	9 October 2023
Letters sent to eligible shareholders	11 October 2023
Retention Forms due date	24 November 2023

The Company reserves the right to change any of the dates referred to in the ASX announcement or this letter and Retention Form, or to vary, cancel, or delay the Facility or the sale of the Shares at any time before Shares are sold, by making an announcement to ASX.

The Company does not provide any recommendation or advice as to whether you should sell or retain your Shares.

Enclosed are the terms and conditions relating to the Facility which answers questions that you may have with respect to the sale of Unmarketable Parcels. These terms and conditions are important. If you are in doubt about what to do, you should consult your legal, financial or taxation adviser.

If you have any questions about the operation of the Facility, please contact the Company at info@antisense.com.au or at (03) 9827 8999.

Yours faithfully,



Phillip Hains
Company Secretary
Antisense Therapeutics Limited

Unmarketable Parcels Share Sale Facility

Terms and Conditions

What is an Unmarketable Parcel?

An unmarketable parcel is a holding of fully paid ordinary shares in the Company (**Shares**) that is valued at less than \$500 (**Unmarketable Parcel**). Based on the closing price of Shares on 6 October 2023 (**Record Date**) of \$0.07, this is equivalent to a holding of less than 7,143 Shares.

Why has the Facility been established?

The Company has decided to establish an Unmarketable Parcel share sale facility (**Facility**) to enable you to sell your Unmarketable Parcel without incurring brokerage or handling costs that could otherwise make a sale of your Unmarketable Parcel uneconomic or difficult. The sale of Unmarketable Parcels through the Facility will also enable the Company to reduce administrative costs associated with maintaining a large number of relatively small holdings of Shares.

Does the Company have the authority to establish the Facility?

The Company has the ability to establish the Facility and facilitate the sale of the Unmarketable Parcels under clause 8A of the Company's constitution and rule 15.13 of the ASX Listing Rules.

MY ELIGIBILITY

Why have I received this letter?

You have received this letter because our records indicate that you held an Unmarketable Parcel of Shares based on the price of Shares as at close of trade on the Record Date.

What if the price of Shares changes between the Record Date and the Closing Date?

If the market price of Shares increases between the Record Date and the Closing Date, such that at the Closing Date the value of your Shares is equal to or

greater than \$500, your Shares will not be sold through the Facility.

If I buy more Shares in the Company, will I retain my holding?

The Company will not sell your Shares if you increase your holding to a marketable parcel, being a holding of Shares with a market value of at least \$500 based on the price of Shares as at the Closing Date.

Please note that any additional Shares acquired must be registered by the Closing Date, under the same name and address and with the same holder number (SRN or HIN) as set out in the enclosed Retention Form.

What if I sell my shares before the Facility Closing Date?

If you sell all your Shares prior to the Closing Date, no further action will be taken by the Company.

What if I hold multiple Unmarketable Parcels of Shares?

If you hold multiple Unmarketable Parcels of Shares, you must complete and return a Retention Form for each separate Unmarketable Parcel that you wish to retain.

Alternatively, you may aggregate your multiple holdings to avoid them being sold. To do this, please contact the Share Registry on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia). If you wish to sell your Unmarketable Parcel through the Facility, you should take no action.

What if my holding of Shares in the Company is a CHESS Holding?

If your Shares remain in a CHESS Holding, the Company may move those Shares to an Issuer Sponsored Holding and the Shares will then be sold under the Facility.

MY PARTICIPATION

What are the advantages and disadvantage of participating in the Facility?

You may consider the following consequences of participating in the Facility to be advantageous to you:

- receiving a cash payment from the sale of your Unmarketable Parcel;
- avoiding any brokerage or related selling expenses in connection with the sale of your Shares; and
- utilising a cost-effective way of disposing of an Unmarketable Parcel.

You may consider the following consequences of participating in the Facility to be disadvantageous to you:

- no longer holding any Shares in the Company (unless you subsequently buy more shares or hold Shares under a different holder);
- possible capital gains tax being payable by you;
- the price of the Company's Shares subsequently rising following the sale of your Shares (although there is no way of predicting whether this would actually occur).

Do I need to pay anything if I participate in the Facility?

The Company will pay all costs and expenses arising in connection with the Facility. Any tax payable, or other tax consequences from the sale, will be your responsibility.

What do I need to do to sell my Shares?

If you wish to sell your Shares you should **TAKE NO ACTION**. Your Shares will be sold through the Facility unless a duly completed Retention Form in respect of your Shares is received by the Company's register, Boardroom Pty Limited (**Share Registry**) before 5pm (AEDT) on Friday 24 November 2023 (**Closing Date**) in accordance with the instructions on the Retention Form. A Retention Form is enclosed with this letter.

What if I do not wish to sell my Unmarketable Parcel?

If you do not wish to sell your Shares, you **MUST OPT-OUT** of the Facility by completing and returning the enclosed Retention Form to the address provided in the Retention Form so that it is received by the Share Registry prior to the Closing Date. If the Share Registry has not received your Retention Form by the Closing Date, your Shares will be sold through the Facility.

Alternatively, you can purchase more Shares on-market so that you hold at least \$500 worth of Shares as at the Closing Date.

How will my shares be sold under the Facility?

The Company may arrange for the sale of the Shares under the Facility by way of on-market, or in any way they consider reasonable in the circumstances (e.g. off-market sale).

What price will I receive for Shares sold through the Facility?

The price to be paid for the Shares sold under the Facility has not been fixed. It will depend on when and how the Shares are sold. While the Company will endeavour to procure the best price for the Shares, there can be no assurance as to what this price will be, or that it will be the best possible price.

If the Shares are sold on-market, the price received for them will depend on market conditions at the time of sale, as well as a number of other relevant factors. However, if the Shares are not sold on-market, the price will be the price that the Company have been able to negotiate with the acquirer(s).

You will not have control over the time or price at which your Shares are sold, and the price you receive may not reflect the price of Shares appearing in the media or quoted by the ASX on any given day, nor be the best prices for Shares available on the day your Shares are sold.

When will I receive the proceeds for the Shares sold?

The Company is unable to provide an indication on timing on when you will receive the proceeds for the Shares sold through the Facility. The proceeds from the sale of Shares through the Facility will be dealt with in accordance with the Company's constitution and will be remitted to participating shareholders as soon as practicable following settlement of all Shares sold through the Facility and upon receipt by the Company's Share Register

of instructions from you as to how the payment is to be dealt with.

If you have been issued with a share certificate or certificates, your instructions must be accompanied by the share certificate or certificates relating to the shares that have been sold or, if the certificate or certificates has or have been lost or destroyed, by a statement and undertaking under section 1070D(5) of the Corporations Act 2001 (Cth), to be effective.

In order to provide your instructions as to how the payment is to be dealt with, please call the Share Registry shareholder information line on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia).

Other information

ANP does not make any recommendation or advice regarding whether to retain your Shares or permit them to be sold under the Facility. You should consider seeking independent financial and taxation advice before making a decision as to whether or not to participate in this program. ANP does not accept any liability regarding the price at which shares are sold through the Facility.

You can obtain up-to-date information on the market price of ANP shares by visiting the ASX website (www.asx.com.au) or contacting your financial adviser.

Antisense Therapeutics Limited

ABN 41 095 060 745

All correspondence to

Boardroom Pty Limited

GPO Box 3993

Sydney NSW 2001

Tel: 1300 737 760 (within Aust)

Tel: + 61 2 9290 9600 (outside Aust)

Fax: + 61 2 9279 0664

www.boardroomlimited.com.au

corporateactions@boardroomlimited.com.au

Subregister

SRN/HIN.

Share Retention Form

IMPORTANT: This is an important document and requires your immediate attention. Antisense Therapeutics Limited (**Company**) is implementing a sale facility for holders of parcels of the Company's shares valued at less than \$500 (**Sale Facility**). Further details regarding the Sale Facility are set out in the letter and Notice of Divestiture to you from the Company dated 9 October 2023, which accompanies this form. If you do not want the parcel of shares in the Company referred to below sold under the Sale Facility, you must complete this form and return it so that it is received by the Company's share registry no later than 5.00pm (AEDT) on 24 November 2023. If you are in any doubt as to how to deal with this form, you should consult your professional adviser.

If your holding of the Company's shares increases to more than \$500 by on market purchases or otherwise, then your holding will not be sold under the Sale Facility.

A Number of shares held as at Record Date

The number of shares that you held at 7pm on 6 October 2023:

B Retention of shares

☐

I / We refer to the letter and Notice of Divestiture from the company dated 9 October 2023 and hereby give notice that we would like to retain my / our shares.

C Contact details (Enter your contact details below)

CONTACT NAME	TELEPHONE WORK	TELEPHONE HOME	EMAIL ADDRESS
	()	()	

D Shareholder Signature

By signing and returning this form, I/we confirm that I/we understand that my/our shares will **NOT BE SOLD** under the Sale Facility.

Individual or Securityholder 1

Sole Director and Sole Company Secretary

Securityholder 2

Director

Securityholder 3

Director/Company Secretary

Day

Month

Year

**This form must be received by no later than 5.00pm on
Friday 24 November 2023**

LODGEMENT INSTRUCTIONS ARE ON THE REVERSE OF THIS FORM

Additional information

How to complete this form

- A. This is the number of shares that you held at 7pm on 6 October 2023.
- B. If you would like to retain your shares, please mark the box on the front of this form and return it to the Company's share registry in accordance with the lodgement instructions below. If this form is not received by 5.00pm (AEDT) on Friday 24 November 2023, and you have not otherwise validly notified the Company that you wish to retain your shares, the Company will be entitled to sell your shares on your behalf. **IF YOU WOULD LIKE THE COMPANY TO SELL YOUR SHARES, YOU SHOULD NOT COMPLETE THIS FORM.**
- C. Enter your **contact details** so we may contact you regarding your form.
- D. The form **must** be signed. In the spaces provided you must sign this form as follows:

Individual: Where the holding is in only one name, this form is to be signed by the securityholder.

Joint Holding: Where the holding is in more than one name, all the securityholders must sign.

Power of Attorney: To sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that person. **Please indicate the office held by signing in the appropriate place.**

Lodgement of this Form

If you wish to retain your shares, this form must be completed and returned to the share registry by no later than 5.00pm (AEDT) on Friday 24 November 2023. If you are returning your form by post, please allow sufficient time for collection and delivery by postal services. The postal rule does not apply, which means that to be valid your completed form must be received by no later than 5.00pm (AEDT) on Friday 24 November 2023.

Mailing address:

Antisense Therapeutics Limited
C/- Boardroom Pty Limited
GPO Box 3993
SYDNEY NSW 2001

Delivery address:

Antisense Therapeutics Limited
C/- Boardroom Pty Limited
Level 8
210 George Street
SYDNEY NSW 2000

Consolidation of shareholdings

If you have more than one holding on the Antisense Therapeutics Limited register, you should consider consolidating them. For further information regarding this, please contact Boardroom Pty Limited on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia).

Changes of Address Supported by your Signature(s)

If your address is not exactly as shown, please provide details below. This is only relevant for Issuer Sponsored registered holdings. CHESS holders must notify your sponsoring broker for amendments to holdings on the CHESS Subregister.

CHANGE OF ADDRESS DETAILS – ISSUER SPONSORED ONLY		
SIGN HERE FOR ADDRESS AMENDMENTS:		

Shareholder 1 (Individual) / Sole Director & Sole Company Secretary	Joint Shareholder 2 (Individual) / Director	Joint Shareholder 3 (Individual) / Director/Company Secretary (Delete one)
---	--	--

Privacy Statement

Boardroom Pty Limited advises that Chapter 2C of the *Corporations Act 2001* (Cth) requires information about you as a shareholder (including your name, address and details of the shares you hold) to be included in the public register of the entity in which you hold shares. Information is collected to administer your share holding and if some or all of the information is not collected then it might not be possible to administer your share holding. Your personal information may be disclosed to the entity in which you hold shares. You can obtain access to your personal information by contacting us at the address or telephone number shown on the Application Form. Our privacy policy is available on our website (<https://boardroomlimited.com.au/corp/privacy-policy>).